## Charles F Gilks

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6679805/publications.pdf

Version: 2024-02-01

229 papers

13,445 citations

52 h-index 24982 109 g-index

231 all docs

231 docs citations

times ranked

231

10949 citing authors

#	Article	IF	Citations
1	Human T-cell leukaemia virus type $1$ and Adult T-cell leukaemia/lymphoma in Queensland, Australia: a retrospective cross-sectional study. Sexually Transmitted Infections, 2023, 99, 50-52.	1.9	2
2	Analysis of the COVID-19 pandemic: lessons towards a more effective response to public health emergencies. Globalization and Health, 2022, 18, 10.	4.9	38
3	Improved sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near point of care. Sexually Transmitted Infections, 2021, 97, 471-472.	1.9	6
4	A Meta-analysis on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household Transmission Clusters. Clinical Infectious Diseases, 2021, 72, e1146-e1153.	5.8	137
5	Reasons for Not Seeking Hepatitis C Treatment among People Who Inject Drugs. Substance Use and Misuse, 2021, 56, 175-184.	1.4	2
6	New Insights on Long-Term Hepatitis B Virus Responses in HIV–Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 98-103.	2.1	1
7	Economic evaluation of alternative testing regimes and settings to detect undiagnosed HIV in Australia. BMC Health Services Research, 2021, 21, 30.	2.2	2
8	Reimagining global health systems for the 21st century: lessons from the COVID-19 pandemic. BMJ Global Health, 2021, 6, e004882.	4.7	21
9	Factors associated with pyomyositis: A systematic review and metaâ€analysis. Tropical Medicine and International Health, 2021, 26, 1210-1219.	2.3	8
10	STI and HIV knowledge and testing: a comparison of domestic Australian-born, domestic overseas-born and international university students in Australia. Sexual Health, 2021, 18, 346-348.	0.9	6
11	Online HIV Self-Testing (HIVST) Dissemination by an Australian Community Peer HIV Organisation: A Scalable Way to Increase Access to Testing, Particularly for Suboptimal Testers. International Journal of Environmental Research and Public Health, 2021, 18, 11252.	2.6	9
12	Q fever vaccine efficacy and occupational exposure risk in Queensland, Australia: A retrospective cohort study. Vaccine, 2020, 38, 6578-6584.	3.8	8
13	Ending the epidemic of HIV/AIDS by 2030: Will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many countries?. International Journal of Infectious Diseases, 2020, 100, 273-277.	3.3	51
14	Hepatitis C cascade of care at an integrated community facility for people who inject drugs. Journal of Substance Abuse Treatment, 2020, 114, 108025.	2.8	12
15	Leaving no one behind: lessons from implementation of policies for universal HIV treatment to universal health coverage. Globalization and Health, 2020, 16, 17.	4.9	13
16	Reduced sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care. Sexual Health, 2020, 17, 15.	0.9	16
17	Peer-delivered point-of-care testing for Chlamydia trachomatis and Neisseria gonorrhoeae within an urban community setting: a cross-sectional analysis. Sexual Health, 2020, 17, 359.	0.9	6
18	Global health security and universal health coverage: Understanding convergences and divergences for a synergistic response. PLoS ONE, 2020, 15, e0244555.	2.5	16

#	Article	IF	CITATIONS
19	Primary health care contributions to universal health coverage, Ethiopia. Bulletin of the World Health Organization, 2020, 98, 894-905A.	3.3	37
20	Australian interdisciplinary healthcare providers' perspectives on the effects of broader pre-exposure prophylaxis (PrEP) access on uptake and service delivery: a qualitative study. Sexual Health, 2020, 17, 485.	0.9	7
21	Title is missing!. , 2020, 15, e0244555.		O
22	Title is missing!. , 2020, 15, e0244555.		0
23	Title is missing!. , 2020, 15, e0244555.		0
24	Title is missing!. , 2020, 15, e0244555.		0
25	Title is missing!. , 2020, 15, e0244555.		O
26	Title is missing!. , 2020, 15, e0244555.		0
27	Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners' practices and attitudes. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 436-442.	1.2	4
28	Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min. PLoS ONE, 2019, 14, e0225199.	2.5	2
29	HIV Prevalence Among Tuberculosis Patients in Sub-Saharan Africa: A Systematic Review and Meta-analysis. AIDS and Behavior, 2019, 23, 1561-1575.	2.7	29
30	Towards achieving the fast-track targets and ending the epidemic of HIV/AIDS in Ethiopia: Successes and challenges. International Journal of Infectious Diseases, 2019, 78, 57-64.	3.3	19
31	Integrated HIV self-testing (HIVST) service delivery in Queensland for policy and service development: study protocol. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 207-215.	1.2	5
32	Towards a universal second-line fixed-dose combination ART. Lancet HIV, the, 2018, 5, e3-e5.	4.7	3
33	Seroprevlance of Coxiella burnetii among abattoir and slaughterhouse workers: A meta-analysis. One Health, 2018, 6, 23-28.	3.4	14
34	Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda. International Health, 2018, 10, 8-19.	2.0	6
35	Implications of the on-line market for regulation and uptake of HIV self-testing in Australia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 112-117.	1.2	11
36	The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. BMC Infectious Diseases, 2017, 17, 160.	2.9	3

#	Article	IF	CITATIONS
37	Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. Journal of Antimicrobial Chemotherapy, 2017, 72, 1450-1455.	3.0	15
38	Performance of the Antiretroviral Treatment Program in Ethiopia, 2005-2015: strengths and weaknesses toward ending AIDS. International Journal of Infectious Diseases, 2017, 60, 70-76.	3.3	34
39	Hepatitis B serological markers and plasma DNA concentrations. Aids, 2017, 31, 1109-1117.	2.2	14
40	Implementation of Antiretroviral Therapy for Life in Pregnant/Breastfeeding HIV+ Women (Option B+) Alongside Rollout and Changing Guidelines for ART Initiation in Rural Zimbabwe: The Lablite Project Experience. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 508-516.	2.1	17
41	Second-line antiretroviral therapy: so much to be done. Lancet HIV, the, 2017, 4, e424-e425.	4.7	8
42	Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. International Journal of Drug Policy, 2017, 47, 216-220.	3.3	78
43	Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. International Health, 2017, 9, 91-99.	2.0	8
44	Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke. International Journal of Environmental Research and Public Health, 2017, 14, 799.	2.6	10
45	Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes. Drug and Alcohol Dependence, 2017, 177, 67-70.	3.2	9
46	Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study. BMC Health Services Research, 2016, 16, 660.	2.2	9
47	General Practitioner Antimicrobial Stewardship Programme Study (GAPS): protocol for a cluster randomised controlled trial. BMC Family Practice, 2016, 17, 48.	2.9	6
48	A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. Malawi Medical Journal, 2016, 28, 115-122.	0.6	3
49	Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda. BMC Health Services Research, 2015, 15, 527.	2.2	11
50	The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models. American Journal of Epidemiology, 2015, 182, 633-643.	3.4	16
51	Autopsies and better data on causes of death in Africa. Lancet Infectious Diseases, The, 2015, 15, 492-494.	9.1	5
52	Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. AIDS Research and Human Retroviruses, 2015, 31, 1032-1037.	1.1	15
53	Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. PLoS ONE, 2015, 10, e0137834.	2.5	17
54	Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study. AIDS Research and Therapy, 2014, 11, 32.	1.7	13

#	Article	IF	Citations
55	Exploring the population-level impact of antiretroviral treatment. Aids, 2014, 28, S61-S72.	2.2	14
56	Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial. Aids, 2014, 28, 2579-2588.	2.2	11
57	Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda. Journal of Antimicrobial Chemotherapy, 2014, 69, 1938-1944.	3.0	3
58	High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy. Clinical Infectious Diseases, 2014, 58, 1023-1026.	5.8	36
59	The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe. BMC Health Services Research, 2014, 14, 352.	2.2	25
60	High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial. PLoS ONE, 2014, 9, e90772.	2.5	9
61	Antiretroviral Therapy Uptake, Attrition, Adherence and Outcomes among HIV-Infected Female Sex Workers: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e105645.	2.5	113
62	A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria. PLoS ONE, 2013, 8, e57580.	2.5	17
63	Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial. PLoS Medicine, 2012, 9, e1001217.	8.4	116
64	Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? [Review article]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 6-15.	1.2	30
65	Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara). Antiviral Therapy, 2012, 17, 1363-1373.	1.0	15
66	The charms and challenges of antiretroviral therapy in Uganda: the DART experience. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 137-142.	1.2	21
67	Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. Clinical Infectious Diseases, 2012, 55, 1707-1718.	5.8	68
68	Knowing your HIV/AIDS epidemic and tailoring an effective response: how did India do it?. Sexually Transmitted Infections, 2012, 88, 240-249.	1.9	30
69	Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe. PLoS ONE, 2012, 7, e33672.	2.5	25
70	Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet, The, 2011, 378, 282-284.	13.7	212
71	CD8+T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4+T Cells <200 Cell/Î⅓L: The DART Trial STI Substudy. AIDS Research and Treatment, 2011, 2011, 1-10.	0.7	2
72	Glomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa. Antiviral Therapy, 2011, 16, 1011-1020.	1.0	34

#	Article	IF	CITATIONS
73	Distribution of <i>HLAâ€B</i> alleles in a Ugandan HIVâ€infected adult population: NORA pharmacogenetic substudy of DART. Tropical Medicine and International Health, 2011, 16, 200-204.	2.3	24
74	Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring. Antimicrobial Agents and Chemotherapy, 2011, 55, 4575-4580.	3.2	2
75	Lack of Minority K65R-Resistant Viral Populations Detected After Repeated Treatment Interruptions of Tenofovir/Zidovudine and Lamivudine in a Resource-Limited Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 215-216.	2.1	2
76	Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bulletin of the World Health Organization, 2010, 88, 253-259.	3.3	80
77	Highly active antiretroviral treatment for the prevention of HIV transmission. Journal of the International AIDS Society, 2010, 13, 1-1.	3.0	285
78	Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48â€week randomized comparison with abacavir/zidovudine/lamivudine in HIVâ€infected Ugandan adults with low CD4 cell counts. HIV Medicine, 2010, 11, 334-344.	2.2	24
79	Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudineâ€Lamivudine plus Nevirapine and Zidovudineâ€Lamivudine plus Abacavir. Journal of Infectious Diseases, 2010, 201, 106-113.	4.0	46
80	Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults. Antimicrobial Agents and Chemotherapy, 2010, 54, 2965-2973.	3.2	7
81	Changes in antiretroviral therapy guidelines: implications for public health policy and public purses. Sexually Transmitted Infections, 2010, 86, 388-390.	1.9	3
82	Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 277-283.	2.1	20
83	A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. New England Journal of Medicine, 2010, 362, 812-822.	27.0	321
84	Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet, The, 2010, 375, 123-131.	13.7	267
85	Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet, The, 2010, 375, 1278-1286.	13.7	111
86	DART and laboratory monitoring of HIV treatment – Authors' reply. Lancet, The, 2010, 375, 979-980.	13.7	0
87	The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2009, 21, 903-908.	1.2	26
88	Cost-effectiveness of Strategies for Monitoring the Response to Antiretroviral Therapy in Resource-Limited Settings. Archives of Internal Medicine, 2009, 169, 904.	3.8	2
89	The Global Fight Against HIV/AIDS, Tuberculosis, and Malaria. American Journal of Clinical Pathology, 2009, 131, 844-848.	0.7	158
90	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2009, 9, 409-417.	9.1	216

#	Article	IF	Citations
91	Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, The, 2009, 373, 48-57.	13.7	1,720
92	Can antiretroviral therapy eliminate HIV transmission?. Lancet, The, 2009, 373, 7-9.	13.7	59
93	Universal voluntary HIV testing and immediate antiretroviral therapy – Authors' reply. Lancet, The, 2009, 373, 1080-1081.	13.7	19
94	Twentyâ€fourâ€week safety and tolerability of nevirapine <i>vs.</i> abacavir in combination with zidovudine/lamivudine as firstâ€line antiretroviral therapy: a randomized doubleâ€blind trial (NORA) <sup>*</sup> . Tropical Medicine and International Health, 2008, 13, 6-16.	2.3	27
95	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet, The, 2008, 371, 1443-1451.	13.7	158
96	Monitoring of antiretroviral therapy in low-resource settings – Authors' reply. Lancet, The, 2008, 372, 289.	13.7	2
97	Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infectious Diseases, The, 2008, 8, 516-523.	9.1	681
98	Patterns of Individual and Population-Level Adherence to Antiretroviral Therapy and Risk Factors for Poor Adherence in the First Year of the DART Trial in Uganda and Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 468-475.	2.1	49
99	Severe Renal Dysfunction and Risk Factors Associated with Renal Impairment in HIVâ€Infected Adults in Africa Initiating Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1271-1281.	5.8	134
100	Working with risk: Occupational safety issues among healthcare workers in Kenya. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 304-310.	1.2	38
101	Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans. Aids, 2008, 22, S123-S130.	2.2	28
102	Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/νl. Aids, 2008, 22, 237-247.	2.2	74
103	World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antiviral Therapy, 2008, 13, 15-23.	1.0	89
104	The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy, 2008, 13, 1-13.	1.0	191
105	Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Therapy, 2008, 13, 25-36.	1.0	222
106	World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antiviral Therapy, 2008, 13, 49-57.	1.0	43
107	Estimating Glomerular Filtration Rate in HIV-Infected Adults in Africa: Comparison of Cockcroft–Gault and Modification of Diet in Renal Disease Formulae. Antiviral Therapy, 2008, 13, 761-770.	1.0	32
108	Behaviour change in clients of health centre-based voluntary HIV counselling and testing services in Kenya. Sexually Transmitted Infections, 2007, 83, 541-546.	1.9	34

#	Article	IF	Citations
109	International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. American Journal of Obstetrics and Gynecology, 2007, 197, S42-S55.	1.3	59
110	The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet, The, 2006, 368, 505-510.	13.7	580
111	Susceptibility of healthcare workers in Kenya to hepatitis B: new strategies for facilitating vaccination uptake. Journal of Hospital Infection, 2006, 64, 271-277.	2.9	47
112	National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?. Aids, 2006, 20, 1497-1502.	2.2	52
113	A Polymorphism That Reduces RANTES Expression Is Associated with Protection from Death in HIVâ€Seropositive Ugandans with Advanced Disease. Journal of Infectious Diseases, 2006, 194, 666-669.	4.0	27
114	The lost children of universal access $\hat{a} \in \hat{a}$ issues in scaling-up HIV testing and counselling. Vulnerable Children and Youth Studies, 2006, 1, 44-55.	1.1	12
115	Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial. Antiviral Therapy, 2006, 11, 741-750.	1.0	65
116	Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. Aids, 2005, 19, 163-168.	2.2	67
117	Trends in Adult Medical Admissions in a Rural South African Hospital Between 1991 and 2002. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 53-56.	2.1	17
118	The Role for Government Health Centers in Provision of Same-Day Voluntary HIV Counseling and Testing in Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 329-335.	2.1	24
119	Malaria Attributable to the HIV-1 Epidemic, Sub-Saharan Africa. Emerging Infectious Diseases, 2005, 11, 1410-1419.	4.3	110
120	Conjugate Pneumococcal Vaccine in HIVâ€Infected Ugandans and the Effect of Past Receipt of Polysaccharide Vaccine. Journal of Infectious Diseases, 2005, 192, 1801-1805.	4.0	49
121	Scaling Up Treatment — Why We Can't Wait. New England Journal of Medicine, 2005, 353, 2392-2394.	27.0	32
122	Motherâ€toâ€Child Transmission of Human Herpesvirus–8 in South Africa. Journal of Infectious Diseases, 2004, 190, 1068-1075.	4.0	125
123	A Caseâ€Control Study to Investigate Serological Correlates of Clinical Failure of 23â€Valent Pneumococcal Polysaccharide Vaccine in HIVâ€1–Infected Ugandan Adults. Journal of Infectious Diseases, 2004, 190, 707-712.	4.0	33
124	Polyuria in association with Plasmodium falciparum malaria in a region of unstable transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 255-260.	1.8	5
125	Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 660-670.	1.8	25
126	23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults. Aids, 2004, 18, 1210-1213.	2.2	54

#	Article	IF	CITATIONS
127	HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. Aids, 2004, 18, 547-554.	2.2	173
128	The operation, quality and costs of a district hospital laboratory service in Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 403-408.	1.8	45
129	Eosinophilia and progression to active tuberculosis in HIV-1-infected Ugandans. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 477-480.	1.8	27
130	Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatric Infectious Disease Journal, 2003, 22, 1057-1063.	2.0	79
131	Are intestinal helminths a risk factor for non-typhoidalSalmonellabacteraemia in adults in Africa who are seropositive for HIV? A case-control study. Annals of Tropical Medicine and Parasitology, 2002, 96, 203-208.	1.6	10
132	Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. Health Policy and Planning, 2002, 17, 187-195.	2.7	69
133	Carriage of Potentially Pathogenic Escherichia coli in Chickens. Avian Diseases, 2002, 46, 721-724.	1.0	18
134	Effect of Human Immunodeficiency Virus (HIV) Type 1 Envelope Subtypes A and D on Disease Progression in a Large Cohort of HIVâ€1–Positive Persons in Uganda. Journal of Infectious Diseases, 2002, 185, 1244-1250.	4.0	227
135	Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. Aids, 2002, 16, 1633-1641.	2.2	238
136	Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. Aids, 2002, 16, 1031-1038.	2.2	353
137	Costs of hospital care for HIV-positive and HIV-negative patients at Kenyatta National Hospital, Nairobi, Kenya. Aids, 2002, 16, 901-908.	2.2	21
138	Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. Aids, 2002, 16, 1409-1417.	2.2	73
139	Protein conjugate pneumococcal vaccines. BMJ: British Medical Journal, 2002, 324, 750-751.	2.3	7
140	A CD45 polymorphism associated with abnormal splicing is absent in African populations. Immunogenetics, 2002, 53, 980-983.	2.4	22
141	Chemokine-receptor genes and AIDS risk. Nature, 2002, 417, 140-140.	27.8	22
142	Diarrhoea, CD4 Counts and Enteric Infections in a Community-Based Cohort of HIV-Infected Adults in Uganda. Journal of Infection, 2002, 45, 99-106.	3.3	79
143	The radiographic appearance of pneumococcal pneumonia in adults is unaltered by HIV-1-infection in hospitalized Kenyans. Aids, 2002, 16, 2095-2096.	2.2	8
144	Man, monkeys and malaria. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 921-922.	4.0	1

#	Article	IF	Citations
145	Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries. Current Opinion in Infectious Diseases, 2001, 14, 507-512.	3.1	20
146	Use of clinical judgement to guide administration of blood transfusions in Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 510-512.	1.8	22
147	Trends in Bloodstream Infections among Human Immunodeficiency Virus–Infected Adults Admitted to a Hospital in Nairobi, Kenya, during the Last Decade. Clinical Infectious Diseases, 2001, 33, 248-256.	5.8	98
148	Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. Aids, 2001, 15, 899-906.	2.2	203
149	HIV care in non-industrialised countries. British Medical Bulletin, 2001, 58, 171-186.	6.9	8
150	Evaluation of microscope condition in Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 583-584.	1.8	33
151	Fresh from the field: some controversies in tropical medicine and hygiene. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 233-237.	1.8	31
152	Rhodococcus equi and HIV-1 Infection in Uganda. Journal of Infection, 2000, 41, 227-231.	3.3	26
153	Genotypic Analysis of Multidrug-Resistant Salmonella enterica Serovar Typhi, Kenya. Emerging Infectious Diseases, 2000, 6, 649-651.	4.3	48
154	Paediatric HIV infection in a rural South African district hospital. Journal of Tropical Pediatrics, 2000, 46, 107-110.	1.5	31
155	The changing impact of HIV/AIDS on Kenyatta National Hospital, Nairobi from 1988/89 through 1992 to 1997. Aids, 2000, 14, 1625-1631.	2.2	28
156	An Improved Algorithm for Determining HIV Type 1 Subtypes in a Primary Laboratory in Uganda. AIDS Research and Human Retroviruses, 2000, 16, 621-625.	1.1	13
157	23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet, The, 2000, 355, 2106-2111.	13.7	450
158	HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 Polymorphism Detected by PCR-SSP in a Semi-Urban HIV-Positive Ugandan Population. Experimental and Clinical Immunogenetics, 1999, 16, 17-25.	1.2	8
159	Admission Trends in a Rural South African Hospital During the Early Years of the HIV Epidemic. JAMA - Journal of the American Medical Association, 1999, 282, 1087.	7.4	46
160	Analysis of Salmonella enterica serotype Typhimurium by phage typing, antimicrobial susceptibility and pulsed-field gel electrophoresis. Journal of Medical Microbiology, 1999, 48, 1037-1042.	1.8	30
161	Economic issues and antiretroviral therapy in developing countries. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 1-3.	1.8	13
162	Inverse association between BCG immunisation and intestinal nematode infestation among HIV-1-positive individuals in Uganda. Lancet, The, 1999, 354, 1000-1001.	13.7	49

#	Article	IF	Citations
163	Pneumococcal Disease in Sub-Saharan Africa: Could Currently Available Vaccines Avert a Crisis?. Tropical Doctor, 1999, 29, 5-7.	0.5	O
164	Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. Journal of Infection, 1998, 37, 48-53.	3.3	86
165	Increasing frequency of tuberculosis among staff in a South African district hospital: impact of the HIV epidemic on the supply side of health care. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 500-502.	1.8	25
166	Some Effects of the Rising Case Load of Adult HIV-Related Disease on a Hospital in Nairobi. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 234-240.	0.3	27
167	Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa. Aids, 1998, 12, 1675-1682.	2.2	46
168	Acute bacterial infections and HIV disease. British Medical Bulletin, 1998, 54, 383-393.	6.9	36
169	Pneumococcal vaccination in HIV-1-infected adults in Uganda. Aids, 1998, 12, 1683-1689.	2.2	47
170	Reducing the risk of nosocomial HIV infection in British health workers working overseas: role of post-exposure prophylaxis. BMJ: British Medical Journal, 1998, 316, 1158-1160.	2.3	20
171	Responsiveness of Human Immunodeficiency Virus Type 1â€Infected Kenyan Women with or without Prior Pneumococcal Disease to Pneumococcal Vaccine. Journal of Infectious Diseases, 1997, 175, 975-978.	4.0	43
172	The risks and benefits of childhood bacille Calmette-Gu $\tilde{A}$ @rin immunization among adults with AIDS. Aids, 1997, 11, 669-672.	2.2	25
173	Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults. Aids, 1997, 11, 875-882.	2.2	130
174	Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. Aids, 1997, 11, 911-918.	2.2	37
175	Improving HIV/AIDS disease surveillance in low-income countries. Aids, 1997, 11, 1881-1882.	2.2	2
176	Testing sputum samples for HIV antibodies, using a rapid, saliva-card test system. Annals of Tropical Medicine and Parasitology, 1997, 91, 115-117.	1.6	2
177	Tropical medicine in the HIV/AIDS era. Lancet, The, 1997, 349, S17-S18.	13.7	3
178	Clinical, epidemiological and preventative aspects. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 627-631.	1.8	11
179	Acute Bacterial Infections., 1997,, 235-250.		0
180	Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet, The, 1996, 347, 718-723.	13.7	195

#	Article	IF	CITATIONS
181	Pneumocystis carinii pneumonia in Africa. Lancet, The, 1996, 347, 126-127.	13.7	4
182	Lessons to be learned from tuberculosis control in China. Lancet, The, 1996, 347, 835-836.	13.7	2
183	The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. Aids, 1996, 10, 1025-1032.	2.2	96
184	No increased prevalence of adrenocortical insufficiency in human immunodeficiency virus-associated tuberculosis. Tubercle and Lung Disease, 1996, 77, 444-448.	2.1	11
185	Serotypes and antibiotic susceptibilities of Streptococcus pneumoniae in Nairobi, Kenya. Journal of Infection, 1996, 32, 139-142.	3.3	27
186	Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma. British Journal of Clinical Pharmacology, 1996, 41, 160-162.	2.4	7
187	Molecular typing of multi-drug resistant Shigella dysenteriae type 1 by plasmid analysis and pulsed-field gel electrophoresis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 712-714.	1.8	23
188	Bacteriuria in a cohort of predominantly HIV-1 seropositive female commercial sex workers in Nairobi, Kenya. Journal of Infection, 1996, 33, 33-37.	3.3	19
189	Multi-drug resistant non-typhi salmonellae in Kenya. Journal of Antimicrobial Chemotherapy, 1996, 38, 425-434.	3.0	44
190	Disseminated Mycobacterium avium Infection Among HIV-Infected Patients in Kenya. Journal of Acquired Immune Deficiency Syndromes, 1995, 8, 195???198.	0.3	54
191	Serological responses to brucellosis in HIV-seropositive patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 228-230.	1.8	21
192	Nasopharyngeal carriage of Staphylococcus aureus and carriage of tetracycline-resistant strains associated with HIV-seropositivity. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 34-40.	2.9	29
193	Characterization of Streptococcus pneumoniae from Human Immunodeficiency Virus-Seropositive Patients with Acute and Recurrent Pneumonia. Journal of Infectious Diseases, 1995, 172, 983-987.	4.0	23
194	Impact of HIV in sub-Saharan Africa. Lancet, The, 1995, 346, 187.	13.7	4
195	Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity. Lancet, The, 1995, 346, 1034-1035.	13.7	38
196	Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. Tubercle and Lung Disease, 1994, 75, 199-202.	2.1	37
197	Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. Aids, 1994, 8, 779-786.	2.2	39
198	Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet, The, 1993, 342, 332-337.	13.7	130

#	Article	IF	Citations
199	The clinical challenge of the HIV epidemic in the developing world. Lancet, The, 1993, 342, 1037-1039.	13.7	60
200	Spontaneous and induced abortions at Kenyatta National Hospital, Nairobi, Kenya. International Journal of Gynecology and Obstetrics, 1993, 41, 182-183.	2.3	5
201	Evidence of Previous Infection with Mycobacterium avium-Mycobacterium intracellulare Complex among Healthy Subjects: An International Study of Dominant Mycobacterial Skin Test Reactions. Journal of Infectious Diseases, 1993, 168, 1553-1558.	4.0	80
202	Pneumococcal Disease and HIV Infection. Annals of Internal Medicine, 1993, 118, 393.	3.9	12
203	Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. Journal of Clinical Microbiology, 1993, 31, 3227-3230.	3.9	196
204	HIV disease in Africa. Revista Da Sociedade Brasileira De Medicina Tropical, 1993, 26, 135-139.	0.9	0
205	Geographic Diversity of Human Immunodeficiency Virus Type 1: Serologic Reactivity to env Epitopes and Relationship to Neutralization. Journal of Infectious Diseases, 1992, 165, 256-261.	4.0	51
206	Biochemical mis-identification of Brucella melitensis and subsequent laboratory-acquired infections. Journal of Hospital Infection, 1992, 22, 159-162.	2.9	58
207	Tuberculosis in perspective. Lancet, The, 1992, 339, 748.	13.7	4
208	Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet, The, 1991, 337, 627-630.	13.7	190
209	A Practical Approach to the Clinical Problems of the HIV-Infected Adult in the Tropics. Tropical Doctor, 1991, 21, 90-97.	0.5	8
210	Comparative humoral responses to HIV-1 p24gag and gp120env in subjects from East Africa and the UK. Aids, 1991, 5, 1015-1020.	2.2	6
211	No association between meningococcal disease and human immunodeficiency virus in adults in Nairobi, Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 651.	1.8	22
212	Toxoplasma antibodies in HIV-positive patients from Nairobi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 750-751.	1.8	22
213	AIDS, monkeys and malaria. Nature, 1991, 354, 262-262.	27.8	16
214	Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. Aids, 1990, 4, 981-986.	2.2	94
215	Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet, The, 1990, 336, 545-549.	13.7	290
216	Relationships between sequestration, antigenic variation and chronic parasitism in Plasmodium chabaudi– a rodent malaria model. Parasite Immunology, 1990, 12, 45-64.	1.5	118

#	Article	IF	CITATIONS
217	Host diet in experimental rodent malaria: a variable which can compromise experimental design and interpretation. Parasitology, 1989, 98, 175-177.	1.5	12
218	CYCADS AND SAGO. Lancet, The, 1988, 331, 181-182.	13.7	1
219	Failure of penicillin prophylaxis in laboratory acquired leptospirosis Postgraduate Medical Journal, 1988, 64, 236-238.	1.8	22
220	DOXYCYCLINE PROPHYLAXIS IN MALARIA. Lancet, The, 1987, 329, 1487.	13.7	2
221	Amodiaquine and malaria prophylaxis. Parasitology Today, 1986, 2, 209-211.	3.0	3
222	Points: More than just "no tobacco": Oxfam's Stewardship Fund. BMJ: British Medical Journal, 1985, 291, 827-827.	2.3	0
223	The Nuclear Arms Race and the Third World. JAMA - Journal of the American Medical Association, 1985, 254, 608.	7.4	0
224	CLUSTERS OF SHINGLES. Lancet, The, 1985, 326, 1433-1434.	13.7	2
225	Mixed malarial infection due to Plasmodium falciparum and P vivax BMJ: British Medical Journal, 1985, 291, 603-604.	2.3	2
226	Typhoid: an unusual cause of gastrointestinal bleeding. British Journal of Radiology, 1984, 57, 344-346.	2.2	7
227	Skin reactions to bug bites as a result of xenodiagnosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1981, 75, 405-408.	1.8	31
228	The Presentation and Outcome of HIV-related Disease in Nairobi. QJM - Monthly Journal of the Association of Physicians, $0$ , , .	0.5	15
229	Attributes of national governance for an effective response to public health emergencies: Lessons from the response to the COVID-19 pandemic. Journal of Global Health, 0, 12, .	2.7	4